A novel polyplex nanoparticle formulated at the NCL is shown to inhibit growth of pancreatic cancer and prevent metastasis in mice. The study was co-lead by Dr. Jill Smith of Georgetown University and Lombardi Comprehensive Cancer Center and NCL’s Pharmacology and Toxicology Section Head Dr. Stephan Stern. The results of the study were recently published in Cellular and Molecular Gastroenterology and Hepatology.
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer.
Burks, J., Nadella, S., Mahmud, A., Mankongpaisarnrung, C., Wang, J., Hahm, J.-I., Tucker, R.D., Shivapurkar, N., Stern, S.T., and Smith, J.P.
Cellular and Molecular Gastroenterology and Hepatology, 2018, 6(1), 17-32.
Read a recent highlight of the project on the Frederick National Laboratory website: https://frederick.cancer.gov/news/new-nanoparticle-inhibits-growth-pancreatic-cancer-mice.